secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001628280-25-045157
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics posts Phase 1 cemsidomide data in RRMM; terminates TD Cowen ATM prospectus
--------------------------------------------------------------------------------

- Posted Phase 1 data for cemsidomide + dex in relapsed/refractory multiple myeloma; presentation on IR website.
- Terminated sales agreement prospectus with TD Cowen effective Oct 16, 2025; underlying agreement remains in effect.
- Previously issued 3,769,483 shares under TD Cowen ATM for gross proceeds of $9.6M as of June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025045157/0001628280-25-045157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025045157/cccc-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-045157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer